Ziprasidone: A novel psychotropic with unique properties

Expert Review of Neurotherapeutics

Volumn 4, Issue 2, 2004, Pages 179-186

  Ballas, Christos ^a   Yang, Calvin ^b   O'Reardon, John ^b   Ballas, Paul ^b   Baldassano, Claudia ^b  

^a Ravdin Building   (United States)

^b NONE   (United States)

Author keywords

Dose; Effects; Schizophrenia; Treatment; Ziprasidone

Indexed keywords

ALDEHYDE OXIDASE; AMFEBUTAMONE; ANTACID AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUSPIRONE; CARBAMAZEPINE; CHOLESTEROL; CIMETIDINE; CLOZAPINE; CYTOCHROME P450; CYTOCHROME P450 3A4; DOPAMINE; DOPAMINE RECEPTOR; HALOPERIDOL; HISTAMINE H1 RECEPTOR; KETOCONAZOLE; LIPID; NEFAZODONE; NEUROLEPTIC AGENT; OLANZAPINE; OPIATE; ORAL CONTRACEPTIVE AGENT; PLASMA PROTEIN; QUETIAPINE; RISPERIDONE; SEROTONIN; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; UNINDEXED DRUG; ZIPRASIDONE;

AKATHISIA; BIPOLAR MANIA; CLINICAL TRIAL; DEPRESSION; DRUG BIOAVAILABILITY; DRUG RECEPTOR BINDING; EOSINOPHILIA; EXTRAPYRAMIDAL SYMPTOM; HEADACHE; HUMAN; NONHUMAN; RESPIRATORY TRACT DISEASE; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SOMNOLENCE; TORSADE DES POINTES; XEROSTOMIA;

ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS; HUMANS; MENTAL DISORDERS; PIPERAZINES; SCHIZOPHRENIA; THIAZOLES;

EID: 1542344432     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.4.2.179     Document Type: Review

References (43)

1. Miceli JJ, Hunt T, Cole MJ et al. The pharmacokinetics (PK) of CP 88,059 (CP) in healthy male volunteers following oral (PO) and intravenous (IV) administration. Clin. Pharmacol. Ther. 55, 142 (1994).
2. Miceli JJ, Wilner KD, Hansen, RA et al. Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers. Br. J. Clin. Pharmacol. 49, 5-15 (2000).
3. Wilner KD, Tensfeldt TG, Baris B et al. Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers. Br. J. Clin. Pharmacol. 49, 15-20 (2000)
4. Everson G, Lasseter KC, Anderson KE et al. The pharmacokinetics of ziprasidone in subjects with normal and impaired hepatic function. Br. J. Clin. Pharmacol. 49, 21-26 (2000).
5. Aweeka F, Jayesekara D, Horton M et al. The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. Br. J. Clin. Pharmacol. 49, 27-33 (2000).
6. Beedham C, Miceli JJ, Obach RS. Ziprasidone metabolism, aldehyde oxidase, and clinical implications. J. Clin. Psychopharmacol. 23, 229-232 (2003). An elaboration of ziprasidone's metabolism and the relevant clinical sequelae.
7. Prakash C, Kamel A, Cui D, Whalen RD, Miceli JJ, Tweedie D. Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. Br. J. Clin. Pharmacol. 49, 35-42 (2000).
8. Miceli JJ, Smith M, Robarge L, Morse T, Laurent A. The effects of ketoconazole on ziprasidone pharmacokinetics - a placebo-controlled crossover study in healthy volunteers Br. J. Clin. Pharmacol. 49, 71-76 (2000).
9. Wilner KD, Hansen RA, Folger CJ, Geoffroy, P. The pharmacokinetics of ziprasidone in healthy volunteers treated with cimetidine or antacid. Br. J. Clin. Pharmacol. 49, 57-60 (2000).
10. Muirhead GJ, Harness J, Holt PR, Oliver S, Anziano RJ. Ziprasidone and the pharmacokinetics of a combined oral contraceptive. Br. J. Clin. Pharmacol. 49, 49-56 (2000).
11. Wilner KD, Demattos SB, Anziano Rj, Apseloff G, Gerber N. Ziprasidone and the activity of cytochrome P450 2D6 in healthy extensive metabolizers. Br. J. Clin. Pharmacol. 49, 43-47 (2000).
12. Apseloff G, Mullet D, Wilner KD et al. The effects of ziprasidone on steady state lithium levels and renal clearance of lithium Br. J. Clin. Pharmacol. 49, 61-64 (2000).
13. Seeger TF, Seymour PA, Schmidt AW et al. Ziprasidone (CP-88,059), a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J. Pharmacol. Experiment. Ther. 275, 101-113 (1995).
14. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors: focus on newer generation compounds. Life Sci. 68, 29-39 (2000).
15. Schmidt AW, Lebel LA, Howard HR et al. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur. J. Pharmacol. 425, 197-201 (2001).
16. 11C-raclopride. Psychopharmacology 112, 308-314 (1993).
17. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors: focus on newer generation compounds. Life Sci. 68, 29-39 (2000).
18. 2 receptors: an autoradiographic analysis in rat brain. Brain Res. Bull. 16, 517-525 (1986).
19. 1A receptor activation contributes to ziprasidone-influenced dopamine release in the rat prefrontal cortex. Biological Psych. 48, 229-237 (2000).
20. Murray S, Siu Co, Romano SJ. Optimal dosing of oral ziprasidone: Analysis of clinical trial data. Poster presented at Annual Meeting of the American Psychiatric Association, CA, USA. 17-22 May (2003).
21. Hirsch SR, Kissling W, Bauml J, Power A, O'Connor R. A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. J. Clin. Psych. 63(6), 516-523 (2002).
22. Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology 20(5), 491-505 (1999).
23. Addington D, Pantelis C, Dineen M, Benattia M, Romano SJ, Murray S. Ziprasidone vs. risperidone in schizophrenia: 52 weeks' comparative data. Presented at the Annual Meeting of the American Psychiatric Association, CA, USA. 17-22 May (2003).
24. Arato M, O'Connor R, Meltzer HY, ZEUS Study Group. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int. Clin. Pychopharmacol. 17(5), 207-215 (2002). The major clinical trial detailing ziprasidone's efficacy and side effects.
25. Keck PE Jr, Reeves KR, Harrigan EP, Ziprasidone Study Group. Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double-blind, placebo-controlled, multicenter studies. J. Clin. Psychopharmacol. 21(1), 27-35 (2001). Represents the major study of ziprasidone in the treatment of schizoaffective disorder.
26. Weiden PJ, Simpson GM, Potkin SG, O'Sullivan RL. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. J. Clin. Psych. 64(5), 580-588 (2003).
27. Kaye NS. Ziprasidone augmentation of dozapine in 11 patients. J. Clin. Psych. 64(2), 215-216 (2003).
28. Geodon Package Insert. June (2002).
29. Glick ID, Romano SJ, Simpson G et al. Insulin resistance in olanzapine and ziprasidone treated patients: results of a double-blind, controlled 6 week trial. Presented at the Annual Meeting of the American Psychiatric Association, LA, USA. 5-10 May (2001).
30. Cohen S, Fitzgerald B, Okos A, Khan S, Khan A. Weight, lipids, glucose, and behavioral measures with ziprasidone treatment in a population with mental retardation. J. Clin Psych. 64(1), 60-62 (2003).
31. Carnahan RM, Lund BC, Perry PJ. Ziprasidone, a new atypical antipsychotic drug. Pharmacotherapy 21(6), 717-730 (2001).
32. Micell JJ, Shiovitz T, Swift RH, Anziano RJ, Tensfeldt T. High-dose ziprasidone is associated with marginal additional QTC increase. Presented at the Annual Meeting of the American Psychiatric Association, CA, USA. 17-22 May (2003).
33. Biswas AK, Zabrocki LA, Mayes KL, Morris-Kukoski CL. Cardiotoxicity associated with intentional ziprasidone and bupropion overdose. J. Toxicol. Clin. Toxicol. 41(2), 101-104 (2003).
34. Baldassano CF, Ballas C, Datto SM et al. Ziprasidone-associated mania: a case series and review of the mechanism. Bipolar Dis. 5(1), 72-75 (2003).
35. Nolan BP, Schulte JJ Jr. Mania associated with initiation of ziprasidone, J. Clin. Psych. 64(3), 336 (2003).
36. 2A in mood changes induced by atypical antipsychotics. J. Clin. Psych. 63(12), 1185-1186 (2002).
37. Keck PE Jr, Versiani M, Potkin S, West SA, Giller E, Ice K. Ziprasidone in Mania Study Group. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J. Psych. 160(4), 741-748 (2003). Investigates the efficacy of ziprasidone in the treatment of acute mania. It indicates that doses of more than 120 mg/day may be needed for a robust clinical effect.
38. Kennedy SH, Lam RW. Enhancing outcomes in the management of treatment resistant depression: a focus on atypical antipsychotics. Bipolar Disord 5 (Suppl. 2), 36-47 (2003).
39. Shelton RC, Tollefion GD, Tohen M, et al. A novel augmentation strategy for treating resistant major depression. Am J. Psych. 158(1), 131-134 (2001).
40. McDougle CJ, Kem DL, Posey DJ. Case series: use of ziprasidone for maladaptive symptoms in youths with autism. J. Am. Acad. Child. Adolesc. Psych. 41(8), 921-927 (2002).
41. Cohen S, Firtzgerald B, Okos A, Khan S, Khan A. Weight, lipids, glucose, and behavioral measures with ziprasidone treatment in a population with mental retardation. J. Clin. Psych. 64(1), 60-62 (2003).
42. 2 receptor. Furthermore, it suggests that all other notions (i.e. serotonergic system) do not reflect the reality of lower extrapyramidal symptom rates.
43. Weiden PJ, Daniel DG, Simpson G, Romano SJ. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J. Clin. Psychopharmacol. 23(6), 595-600 (2003).